China Oncology ›› 2022, Vol. 32 ›› Issue (7): 588-595.doi: 10.19401/j.cnki.1007-3639.2022.07.002
• Specialists' Article • Previous Articles Next Articles
CAO Mengxuan1,2()(), HU Can1, ZHANG Yanqiang1, HUANG Ling1, DU Yian1, YU Pengcheng1,3, ZHANG Ruolan1,4, XU Zhiyuan1()(), CHENG Xiangdong1()()
Received:
2022-06-02
Online:
2022-07-30
Published:
2022-08-09
Contact:
XU Zhiyuan, CHENG Xiangdong
E-mail:mengxuan00001@126.com;xuzy@zjcc.org.cn;chengxd@zjcc.org.cn
CLC Number:
CAO Mengxuan, HU Can, ZHANG Yanqiang, HUANG Ling, DU Yian, YU Pengcheng, ZHANG Ruolan, XU Zhiyuan, CHENG Xiangdong. Analysis of risk factors of early recurrence and metastasis after radical resection of gastric cancer[J]. China Oncology, 2022, 32(7): 588-595.
Tab. 1
Clinical data of 188 patients with postoperative recurrence of gastric cancer"
Data | Case n | Data | Case n | |
---|---|---|---|---|
Gender | Body | 48 | ||
Male | 136 | Antrum | 94 | |
Female | 52 | Cardiac | 43 | |
Age/year | Full | 3 | ||
≥60 | 99 | Borrmann type | ||
<60 | 89 | Ⅰ | 4 | |
Chronic illness | Ⅱ | 102 | ||
Yes | 54 | Ⅲ | 52 | |
No | 134 | Ⅳ | 30 | |
Drinking history | Site of recurrence | |||
Yes | 64 | Liver | 30 | |
No | 124 | Abdominal | 95 | |
Smoking history | Other mode | 63 | ||
Yes | 88 | Lymph node metastasis | ||
No | 100 | N0 | 26 | |
Preoperative chemotherapy | N1 | 20 | ||
Yes | 53 | N2 | 40 | |
No | 135 | N3 | 102 | |
Postoperative chemotherapy | Vascular tumor thrombus | |||
Yes | 148 | Positive | 117 | |
No | 40 | Negative | 71 | |
Reconstruction | Nerve infiltration | |||
Billroth Ⅰ | 67 | Positive | 137 | |
Billroth Ⅱ | 21 | Negative | 51 | |
Roux-en-Y | 100 | Serosa infiltration | ||
Tumor length/cm | Positive | 152 | ||
≥3 | 168 | Negative | 36 | |
<3 | 20 | Number of lymph nodes | ||
Signet-ring cell carcinoma | >12 | 51 | ||
Yes | 79 | ≤12 | 137 | |
No | 109 | cTNM stage | ||
Differentiated degree | Ⅰ | 4 | ||
Low-medium | 115 | Ⅱ | 31 | |
Medium-high | 73 | Ⅲ | 148 | |
Primary site | Ⅳ | 5 |
Tab. 2
Comparison of clinicopathological features between early and late recurrence of 188 cases of gastric cancer after operation"
Data | Early recurrence (n=126) | Late recurrence (n=62) | χ2 | P value |
---|---|---|---|---|
Age/year | ||||
≥60 | 68 | 31 | 0.262 | 0.608 |
<60 | 58 | 31 | ||
Gender | ||||
Male | 97 | 39 | 4.118 | 0.042 |
Female | 29 | 23 | ||
Reconstruction | ||||
Billroth Ⅰ | 37 | 30 | 6.607 | 0.037 |
Billroth Ⅱ | 15 | 6 | ||
Roux-en-Y | 74 | 26 | ||
Serosa infiltration | ||||
Positive | 114 | 38 | 22.862 | 0.000 |
Negative | 12 | 24 | ||
Preoperative chemotherapy | ||||
Yes | 27 | 26 | 8.632 | 0.003 |
No | 99 | 36 | ||
Tumor length/cm | ||||
≥3 | 118 | 50 | 7.393 | 0.007 |
<3 | 8 | 12 | ||
Site of recurrence | ||||
Liver | 27 | 3 | 8.561 | 0.014 |
Abdominal | 59 | 36 | ||
Other mode | 40 | 23 | ||
Number of lymph nodes | ||||
>12 | 42 | 9 | 7.443 | 0.006 |
≤12 | 84 | 53 | ||
Differentiated degree | ||||
Low-medium | 87 | 28 | 9.982 | 0.002 |
Medium-high | 39 | 34 |
Tab. 3
Univariate and multivariate analysis of DFS in postoperative patients with gastric cancer"
Data | P value (univariate) | HR (multivariate) | 95% CI (multivariate) | P value (multivariate) |
---|---|---|---|---|
Age/year | ||||
≥60 | 0.532 | |||
<60 | ||||
Gender | ||||
Male | 0.217 | |||
Female | ||||
Preoperative chemotherapy | ||||
Yes | 0.000 | 0.467 | 0.313-0.699 | 0.000 |
No | ||||
Postoperative chemotherapy | ||||
Yes | 0.047 | 0.692 | 0.492-0.973 | 0.034 |
No | ||||
Tumor length/cm | ||||
≥3 | 0.033 | 1.460 | 0.905-2.355 | 0.121 |
<3 | ||||
Number of lymph nodes | ||||
>12 | 0.001 | 1.886 | 1.313-2.709 | 0.001 |
≤12 | ||||
Signet-ring cell carcinoma | ||||
Yes | 0.626 | |||
No | ||||
Primary site | ||||
Body | 0.105 | |||
Antrum | ||||
Cardiac | ||||
Full | ||||
Serosa infiltration | ||||
Positive | 0.000 | 2.047 | 1.333-3.144 | 0.001 |
Negative | ||||
Nerve infiltration | ||||
Positive | 0.020 | 0.802 | 0.557-1.155 | 0.236 |
Negative | ||||
Site of recurrence | ||||
Liver | 0.030 | 1.290 | 1.006-1.654 | 0.045 |
Abdominal | ||||
Other mode | ||||
Differentiated degree | ||||
Low-medium | 0.000 | 1.475 | 1.068-2.037 | 0.018 |
Medium-high | ||||
Vascular tumor thrombus | ||||
Positive | 0.187 | |||
Negative |
[1] |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
doi: 10.3322/caac.21492 |
[2] |
JOHNSTON F M, BECKMAN M. Updates on management of gastric cancer[J]. Curr Oncol Rep, 2019, 21(8): 67.
doi: 10.1007/s11912-019-0820-4 |
[3] |
LIU D, LU M, LI J, et al. The patterns and timing of recurrence after curative resection for gastric cancer in China[J]. World J Surg Oncol, 2016, 14(1): 305.
doi: 10.1186/s12957-016-1042-y |
[4] |
GAO K, WU J. National trend of gastric cancer mortality in China (2003-2015): a population-based study[J]. Cancer Commun, 2019, 39(1): 1-5.
doi: 10.1186/s40880-018-0346-4 |
[5] |
GADDE R, TAMARIZ L, HANNA, et al. Metastatic gastric cancer (MGC) patients: can we improve survival by metastasectomy? A systematic review and meta-analysis[J]. J Surg Oncol, 2015, 112(1): 38-45.
doi: 10.1002/jso.23945 |
[6] |
SHRIDHAR R, ALMHANNA K, HOFFE S E, et al. Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a Surveillance, Epidemiology, and End Results database analysis[J]. Cancer, 2013, 119(9): 1636-1642.
doi: 10.1002/cncr.27927 |
[7] |
CHIANG C Y, HUANG K H, FANG W L, et al. Factors associated with recurrence within 2 years after curative surgery for gastric adenocarcinoma[J]. World J Surg, 2011, 35(11): 2472-2478.
doi: 10.1007/s00268-011-1247-8 |
[8] |
SAKAR B, KARAGOL H, GUMUS M, et al. Timing of death from tumor recurrence after curative gastrectomy for gastric cancer[J]. Am J Clin Oncol, 2004, 27(2): 205-209.
doi: 10.1097/01.coc.0000092703.12189.a2 |
[9] |
LAI J F, KIM S, KIM K, et al. Prediction of recurrence of early gastric cancer after curative resection[J]. Ann Surg Oncol, 2009, 16(7): 1896-1902.
doi: 10.1245/s10434-009-0473-x |
[10] |
YOO C H, NOH S H, SHIN D W, et al. Recurrence following curative resection for gastric carcinoma[J]. Br J Surg, 2000, 87(2): 236-242.
doi: 10.1046/j.1365-2168.2000.01360.x |
[11] |
LEE J H, KIM H I, KIM M G, et al. Recurrence of gastric cancer in patients who are disease-free for more than 5 years after primary resection[J]. Surgery, 2016, 159(4): 1090-1098.
doi: 10.1016/j.surg.2015.11.002 |
[12] |
SPOLVERATO G, EJAZ A, KIM Y, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis[J]. J Am Coll Surg, 2014, 219(4): 664-675.
doi: 10.1016/j.jamcollsurg.2014.03.062 |
[13] |
XU J, SHEN L, SHUI Y J, et al. Patterns of recurrence after curative D2 resection for gastric cancer: implications for postoperative radiotherapy[J]. Cancer Med, 2020, 9(13): 4724-4735.
doi: 10.1002/cam4.3085 |
[14] |
LIEBIG C, AYALA G, WILKS J A, et al. Perineural invasion in cancer: a review of the literature[J]. Cancer, 2009, 115(15): 3379-3391.
doi: 10.1002/cncr.24396 |
[15] |
CHOI J Y, HA T K, KWON S J. Clinicopathologic characteristics of gastric cancer patients according to the timing of the recurrence after curative surgery[J]. J Gastric Cancer, 2011, 11(1): 46-54.
doi: 10.5230/jgc.2011.11.1.46 |
[16] |
BILICI A, SEKER M, USTAALIOGLU B B O, et al. Prognostic significance of perineural invasion in patients with gastric cancer who underwent curative resection[J]. Ann Surg Oncol, 2010, 17(8): 2037-2044.
doi: 10.1245/s10434-010-1027-y |
[17] |
ROVIELLO F, MARRELLI D, DE MANZONI G, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer[J]. Br J Surg, 2003, 90(9): 1113-1119.
doi: 10.1002/bjs.4164 |
[18] | ZHU L C, XU Y S, SHAN Y Q, et al. Intraperitoneal perfusion chemotherapy and whole abdominal hyperthermia using external radiofrequency following radical D2 resection for treatment of advanced gastric cancer[J]. Int J Hyperthermia, 2019, 36(1): 403-407. |
[19] |
GLEHEN O, PASSOT G, VILLENEUVE L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase Ⅲ study[J]. BMC Cancer, 2014, 14: 183.
doi: 10.1186/1471-2407-14-183 |
[20] |
LI F X, ZHANG R P, LIANG H, et al. The pattern and risk factors of recurrence of proximal gastric cancer after curative resection[J]. J Surg Oncol, 2013, 107(2): 130-135.
doi: 10.1002/jso.23252 |
[21] |
KANG W M, MENG Q B, YU J C, et al. Factors associated with early recurrence after curative surgery for gastric cancer[J]. World J Gastroenterol, 2015, 21(19): 5934-5940.
doi: 10.3748/wjg.v21.i19.5934 |
[22] |
EOM B W, YOON H, RYU K W, et al. Predictors of timing and patterns of recurrence after curative resection for gastric cancer[J]. Dig Surg, 2010, 27(6): 481-486.
doi: 10.1159/000320691 |
[23] |
CUNNINGHAM D, ALLUM W H, STENNING S P, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1): 11-20.
doi: 10.1056/NEJMoa055531 |
[24] | YCHOU M, BOIGE V, PIGNON J P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial[J]. J Clin Oncol, 2011, 29(13): 1715-1721. |
[25] |
LUI S A, TAN W B, TAI B C, et al. Predictors of survival outcome following radical gastrectomy for gastric cancer[J]. ANZ J Surg, 2019, 89(1/2): 84-89.
doi: 10.1111/ans.15011 |
[26] |
HEJNA M, WÖHRER S, SCHMIDINGER M, et al. Postoperative chemotherapy for gastric cancer[J]. Oncologist, 2006, 11(2): 136-145.
doi: 10.1634/theoncologist.11-2-136 |
[27] |
LIU T S, WANG Y, CHEN S Y, et al. An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer[J]. Eur J Surg Oncol, 2008, 34(11): 1208-1216.
doi: 10.1016/j.ejso.2008.02.002 |
[28] |
SAKURAMOTO S, SASAKO M, YAMAGUCHI T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine[J]. N Engl J Med, 2007, 357(18): 1810-1820.
doi: 10.1056/NEJMoa072252 |
[29] |
WANG X, ZHAO L, LIU H F, et al. A phase Ⅱ study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer[J]. Br J Cancer, 2016, 114(12): 1326-1333.
doi: 10.1038/bjc.2016.126 |
[30] |
DONG S, YU J R, ZHANG Q, et al. Neoadjuvant chemotherapy in controlling lymph node metastasis for locally advanced gastric cancer in a Chinese population[J]. J Chemother, 2016, 28(1): 59-64.
doi: 10.1179/1973947815Y.0000000028 |
[31] |
BECKER K, LANGER R, REIM D, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases[J]. Ann Surg, 2011, 253(5): 934-939.
doi: 10.1097/SLA.0b013e318216f449 |
[32] |
LEVENSON G, VORON T, PAYE F, et al. Tumor downstaging after neoadjuvant chemotherapy determines survival after surgery for gastric adenocarcinoma[J]. Surgery, 2021, 170(6): 1711-1717.
doi: 10.1016/j.surg.2021.08.021 |
[1] | GAO Heli, XU Jin, YU Xianjun. Updates on the research and management of pancreatic neuroendocrine neoplasm in 2021 [J]. China Oncology, 2022, 32(9): 772-778. |
[2] | ZHANG Rihong, GUO Yu, LIANG Yun, CHEN Luohai, CHEN Jie, WANG Wei. Prognostic significance of adjuvant chemotherapy in patients with gastric neuroendocrine carcinoma [J]. China Oncology, 2022, 32(9): 807-817. |
[3] | CAI Gang, WANG Shubei, CHEN Jiayi. The current data and challenge of radiotherapy in the case management of gastric cancer [J]. China Oncology, 2022, 32(7): 581-587. |
[4] | JIANG Jinling, ZHOU Chenfei, XI Wenqi, SHI Min, GEN Mei, ZHAO Liqin, CAI Qu, JIANG Jinsong, ZHANG Jun. Optimization of 5-FU metronomic chemotherapy strategy and regulation of the immune microenvironment in gastric cancer: an in vivo study [J]. China Oncology, 2022, 32(7): 596-605. |
[5] | QIAN Yao, LIU Feng. Research progress and prospects of neoadjuvant endocrine therapy for breast cancer [J]. China Oncology, 2022, 32(7): 643-649. |
[6] | LIU Yanquan, HU Xiaomei, YIN Yue, LIN Lin, SHEN Jianzhen, CHEN Yuting, TANG Huanwen. A retrospective study and clinical analysis of post-transplant lymphoproliferative disorder [J]. China Oncology, 2022, 32(7): 650-656. |
[7] | QU Yiping, HOU Peng. Genetic characteristics and prognosis of metastatic thyroid cancer in children [J]. China Oncology, 2022, 32(5): 373-379. |
[8] | MA Guang, OU Xiaomin, HU Chaosu, SONG Shaoli, YANG Zhongyi. Value of pretreatment 18F-FLT PET/CT and 18F-FDG PET/CT uptake heterogeneity for early prediction of treatment outcome in locally advanced nasopharyngeal carcinoma [J]. China Oncology, 2022, 32(4): 309-315. |
[9] | YANG Yilan, ZHAO Xu, CHEN Xingxing, WANG Xuanyi, JIN Kairui, ZHANG Zhen, SHAO Zhimin, GUO Xiaomao, YU Xiaoli. A single-center prognotic analysis of breast ductal carcinoma in situ [J]. China Oncology, 2022, 32(3): 228-233. |
[10] | WANG Zimao, CAO Yuan, WANG Qiying. Construction and validation of the survival prediction model for patients with cutaneous spindle cell melanoma [J]. China Oncology, 2022, 32(3): 234-242. |
[11] | CHEN Xi, ZENG Xiaoying, CHEN Jiayan, LIU Fei, TANG Xi. The clinical value of mismatch repair protein combined with serum tumor markers and Ki-67 proliferation index in the prognostic evaluation of colorectal cancer [J]. China Oncology, 2022, 32(3): 243-250. |
[12] | HOU Qinghua, ZHONG Yanfeng, LIU Linzhuang, WU Liusheng, LIU Jixian. Expression, prognostic value of CBX3 in lung adenocarcinoma and its effect on biological behavior of cancer cells [J]. China Oncology, 2022, 32(2): 152-160. |
[13] | MA Yifei , LIANG Xinjun , WEI Shaozhong . Prognostic value of inflammatory and immune markers in resectable colorectal cancer [J]. China Oncology, 2021, 31(9): 845-851. |
[14] | ZHANG Xuecheng , GUAN Xiaohui . Circ_0007142 accelerates epithelial-mesenchymal transition and invasion of gastric cancer cells through sponging miR-647 and regulating CCR8 gene [J]. China Oncology, 2021, 31(8): 714-724. |
[15] | LEI Yajie , GAO Yi , WANG Zhijie , CHENG Xi , YANG Yufei , ZHOU Hongyu , CHEN Lihua , CHEN Yixin , LI Haoran , LI Ziting , WU Xiaohua . Potential role of lymphadenectomy in patients with ovarian cancer (ⅠC-ⅡA): a retrospective trial [J]. China Oncology, 2021, 31(8): 740-745. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd